F-18 FDG PET/CT assessment of gastrointestinal stromal tumor response to sunitinib malate therapy

Clinical Nuclear Medicine

Volumn 33, Issue 3, 2008, Pages 211-212

  Banzo, Ignacio ^a   Quirce, Remedios ^a   Martinez Rodriguez, Isabel ^a   Jimenez Bonilla, Julio ^a   Sainz Esteban, Aurora ^a   Barragan, Jorge ^a   Portilla Quattrociocchi, Humberto ^a   Carril, Jose M ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

F 18 fluorodeoxyglucose; Gastrointestinal stromal tumor; PET oncology; PET CT; Therapy PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; SUNITINIB;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER METASTASIS; LIVER RESECTION; PERITONEUM; POSITRON EMISSION TOMOGRAPHY; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; LIVER NEOPLASMS; MIDDLE AGED; PYRROLES; RADIOPHARMACEUTICALS;

EID: 39749083351     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318162dddb     Document Type: Article

References (9)

1. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24:3245-3251.
2. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031-1039.
3. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760-1764.
4. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for research and treatment of cancer (EORTC) PET study group. Eur J Cancer. 1999;35:1773-1782.
5. Simo M, García JR, Soler M, et al. Role of FDG PET in the staging, recurrence and treatment response to Imatinib (Glivec) in patients with gastrointestinal stromal tumors. Rev Esp Med Nucl. 2006;25:80-88.
6. Zaknun JJ, Kendler D, Moncayo R, et al. F-18 FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-kit-positive tumor patient by Imatinib. Clin Nucl Med. 2005;30:749-751.
7. Garcia-Gonzalez J, Sanchez A, Areces C, et al. Utility of FDG-PET for early evaluation of efficiency of Imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumours. Rev Esp Med Nucl. 2007;26:100-102.
8. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357-365.
9. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32:153-162.